Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification

References

• Bover J, Ureña-Torres P, Lloret MJ, et al. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of cardiovascular calcification. Expert Op Pharmacother. Forthcoming 2016.
   Google Scholar
• Lindner A, Charra B, Sherrard DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697–701.
   PubMed Web of Science ®Google Scholar
• Kooman JP, Kotanko P, Schols AMWJ, et al. Chronic kidney disease and premature ageing. Nat Rev Nephrol. 2014;10:732–742.
   PubMed Web of Science ®Google Scholar
• Kidney Disease/Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:4.
   Web of Science ®Google Scholar
• Martinez-Castelao A, Gorriz JL, Segura-de la Morena J, et al. Consensus document for the detection and management of chronic kidney disease. Nefrologia. 2014;34:243–262.
   PubMed Web of Science ®Google Scholar
• Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69:1945–1953.
   PubMed Web of Science ®Google Scholar
• Kidney Disease/Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;(suppl 117):S1–S130.
   Google Scholar
• Vervloet MG, Massy ZA, Brandenburg VM, et al. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol. 2014;2:427–436.
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Urena-Torres P, Vervloet MG, et al. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? Nephrol Dial Transpl. 2014;29:1815–1820.
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Tomlinson J, Walsh L, et al. Emerging drugs for secondary hyperparathyroidism. Expert Opin Emerg Drugs. 2015;20:197–208.
   PubMed Web of Science ®Google Scholar
• Rodríguez M, Rodríguez-Ortiz ME. Advances in pharmacotherapy for secondary hyperparathyroidism. Expert Opin Pharmacother. 2015;16:1703–1716.
   PubMed Web of Science ®Google Scholar
• Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370–1378.
   PubMed Web of Science ®Google Scholar
• Cernaro V, Santoro D, Lucisano S, et al. The future of phosphate binders: a perspective on novel therapeutics. Expert Opin Investig Drugs. 2014;23:1459–1463.
   PubMed Web of Science ®Google Scholar
• Gorriz JL, Molina P, Cerveron MJ, et al. Vascular calcification in patients with nondialysis CKD over 3 years. Clin J Am Soc Nephrol. 2015;10:654–666.
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7:487–493.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252.
   PubMed Web of Science ®Google Scholar
• Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130–1137.
   PubMed Web of Science ®Google Scholar
• Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268–1277.
   PubMed Web of Science ®Google Scholar
• Andress DL, Norris KC, Coburn JW, et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med. 1989;321:274–279.
   PubMed Web of Science ®Google Scholar
• Lopez I, Mendoza FJ, Aguilera-Tejero E, et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int. 2008;73:300–307.
   PubMed Web of Science ®Google Scholar
• Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transpl. 2011;26:1327–1339.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482–2494.
   PubMed Web of Science ®Google Scholar
• Wheeler DC, London GM, Parfrey PS, et al. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the Evaluation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. J Am Heart Assoc. 2014;3:e001363.
   PubMed Web of Science ®Google Scholar
• Bover J, Urena P, Ruiz-Garcia C, et al. Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2016;11:161–174.
   PubMed Web of Science ®Google Scholar
• Akaberi S, Clyne N, Sterner G, et al. Temporal trends and risk factors for parathyroidectomy in the Swedish dialysis and transplant population – a nationwide, population-based study 1991–2009. BMC Nephrol. 2014;15:75.
   PubMed Web of Science ®Google Scholar
• Tentori F, Wang M, Bieber BA, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephro. 2015;10:98–109.
   PubMed Web of Science ®Google Scholar
• Ishani A, Liu J, Wetmore JB, et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol. 2015;10:90–97.
   PubMed Web of Science ®Google Scholar
• Malindretos P, Sarafidis P, Lazaridis A, et al. A study of the association of higher parathormone levels with health-related quality of life in hemodialysis patients. Clin Nephrol. 2012;77:196–203.
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218.
   PubMed Web of Science ®Google Scholar
• Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transpl. 2011;26:1948–1955.
   PubMed Web of Science ®Google Scholar
• Naves-Diaz M, Passlick-Deetjen J, Guinsburg A, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES study. Nephrol Dial Transpl. 2011;26:1938–1947.
   PubMed Web of Science ®Google Scholar
• Bover J, Ruiz CE, Pilz S, et al. Vitamin D receptor and interaction with DNA: from physiology to chronic kidney disease. In: Ureña P, editor. Vitamin D in chronic kidney disease. Springer; Forthcoming 2016.
   Google Scholar
• Souberbielle J-C, Boutten A, Carlier M-C, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006;70:345–350.
   PubMed Web of Science ®Google Scholar
• Fernandez-Martin JL, Martinez-Camblor P, Dionisi MP, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transpl. 2015;30:1542–1551.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–S201.
   PubMedGoogle Scholar
• Ketteler M, Elder GJ, Evenepoel P, et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a kidney disease: improving global outcomes controversies conference. Kidney Int. 2015;87:502–528.
   PubMed Web of Science ®Google Scholar
• Goldsmith DJA. The case for routine parathyroid hormone monitoring. Clin J Am Soc Nephrol. 2013;8:319–320.
   PubMed Web of Science ®Google Scholar
• Sprague SM, Moe SM. Rebuttal: PTH–a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol. 2013;8:321.
   PubMed Web of Science ®Google Scholar
• Torregrosa J-V, Bover J, Cannata Andia J, et al. Spanish society of nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). Nefrologia. 2011;31(Suppl 1):3–32.
   PubMed Web of Science ®Google Scholar
• Prados-Garrido MD, Bover J, González-Álvarez MT, et al. 2010 - Guía de práctica clínica de la Sociedad Española de Diálisis y Trasplante de las alteraciones del metabolismo mineral y óseo de la enfermedad renal crónica (CKD-MBD). Dial Traspl. 2011;32:108–118.
   Google Scholar
• Bover J, Rodriguez M, Trinidad P, et al. Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat. Kidney Int. 1994;45:953–961.
   PubMed Web of Science ®Google Scholar
• Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int. 2006;70:1358–1366.
   PubMed Web of Science ®Google Scholar
• Danese MD, Kim J, Doan QV, et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis. 2006;47:149–156.
   PubMed Web of Science ®Google Scholar
• Ureña P, Hruby M, Ferreira A, et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol. 1996;7:506–512.
   PubMed Web of Science ®Google Scholar
• Behets GJ, Spasovski G, Sterling LR, et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int. 2015;87:846–856.
   PubMed Web of Science ®Google Scholar
• Craver L, Marco MP, Martinez I, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5–achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007;22:1171–1176.
   PubMed Web of Science ®Google Scholar
• Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–38.
   PubMed Web of Science ®Google Scholar
• Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004–1013.
   PubMed Web of Science ®Google Scholar
• Melamed ML, Michos ED, Post W, et al. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629–1637.
   PubMed Web of Science ®Google Scholar
• Matias PJ, Jorge C, Ferreira C, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol. 2010;5:905–911.
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, et al. Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern Med. 2016;176:1–10.
   PubMed Web of Science ®Google Scholar
• Alvarez JA, Law J, Coakley KE, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2012;96:672–679.
   PubMed Web of Science ®Google Scholar
• Tokmak F, Quack I, Schieren G, et al. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transpl. 2008;23:4016–4020.
   PubMed Web of Science ®Google Scholar
• Dusilová-Sulková S, Šafránek R, Vávrová J, et al. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients. Int Urol Nephrol. 2015;47:169–176.
   PubMed Web of Science ®Google Scholar
• Bhan I, Tamez H, Thadhani R. Impact of new vitamin D data on future studies and treatment. Curr Opin Nephrol Hypertens. 2013;22:377–382.
   PubMed Web of Science ®Google Scholar
• Gallieni M, Kamimura S, Ahmed A, et al. Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol. 1995;268:F746–5.
   PubMed Web of Science ®Google Scholar
• Marco MP, Martinez I, Betriu A, et al. Influence of Bsml vitamin D receptor gene polymorphism on the response to a single bolus of calcitrol in hemodialysis patients. Clin Nephrol. 2001;56:111–116.
   PubMed Web of Science ®Google Scholar
• Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16:1115–1125.
   PubMed Web of Science ®Google Scholar
• Naves-Díaz M, Álvarez-Hernández D, Passlick-Deetjen J, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 2008;74:1070–1078.
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Brancaccio D, Cannella G, et al. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO survey. Nephrol Dial Transpl. 2012;27:3588–3594.
   PubMed Web of Science ®Google Scholar
• Cardús A, Panizo S, Parisi E, et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res. 2007;22:860–866.
   PubMed Web of Science ®Google Scholar
• Mizobuchi M, Finch JL, Martin DR, et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 2007;72:709–715.
   PubMed Web of Science ®Google Scholar
• Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63:1483–1490.
   PubMed Web of Science ®Google Scholar
• Mittman N, Desiraju B, Meyer KB, et al. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. Kidney Int Suppl. 2010;117:S33–S36.
   Google Scholar
• Lund RJ, Andress DL, Amdahl M, et al. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol. 2010;31:165–170.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Curatola G, Panuccio V, et al. Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension. 2014;64:1005–1011.
   PubMed Web of Science ®Google Scholar
• De Borst MH, Hajhosseiny R, Tamez H, et al. Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol. 2013;24:1863–1871.
   PubMed Web of Science ®Google Scholar
• Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446–456.
   PubMed Web of Science ®Google Scholar
• Duranton F, Rodriguez-Ortiz ME, Duny Y, et al. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol. 2013;37:239–248.
   PubMed Web of Science ®Google Scholar
• De Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (London, England). 2010;376:1543–1551.
   PubMed Web of Science ®Google Scholar
• Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307:674–684.
   PubMed Web of Science ®Google Scholar
• Wang AY-M, Fang F, Chan J, et al. Effect of paricalcitol on left ventricular mass and function in CKD–the OPERA trial. J Am Soc Nephrol. 2014;25:175–186.
   PubMed Web of Science ®Google Scholar
• Tamez H, Zoccali C, Packham D, et al. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J. 2012;164:902–9.e2.
   PubMed Web of Science ®Google Scholar
• Hansen D, Rasmussen K, Danielsen H, et al. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int. 2011;80:841–850.
   PubMed Web of Science ®Google Scholar
• Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70:1858–1865.
   PubMed Web of Science ®Google Scholar
• Posner GH, Helvig C, Cuerrier D, et al. Vitamin D analogues targeting CYP24 in chronic kidney disease. J Steroid Biochem Mol Biol. 2010;121:13–19.
   PubMed Web of Science ®Google Scholar
• Sprague SM, Silva AL, Al-Saghir F, et al. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol. 2014;40:535–545.
   PubMed Web of Science ®Google Scholar
• Comprison of i.v CTAP201 and doxercalciferol in subjects with chronic kidney disease and secondary hiperparathyroidism; [ cited 2016 Mar 28]. Available from: http://clinicaltrials.gov/ct2/show/NCT00792857
   Google Scholar
• Zella JB, Plum LA, Plowchalk DR, et al. Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women. Am J Nephrol. 2014;39:476–483.
   PubMed Web of Science ®Google Scholar
• Llach F, Bover J. Renal osteodystrophies. In: Brenner BM, editor. The kidney. 6th ed. Philadelphia (PA): W.B. Saunders Company; 2000. p. 2013–2186.
   Google Scholar
• Wetmore JB, Gurevich K, Sprague S, et al. A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015;10:1031–1040.
   PubMed Web of Science ®Google Scholar
• Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature. 1993;366:575–580.
   PubMed Web of Science ®Google Scholar
• Schwarz P, Body JJ, Cap J, et al. The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. Eur J Endocrinol. 2014;171:727–735.
   PubMed Web of Science ®Google Scholar
• Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation. 2015;132:27–39.
   PubMed Web of Science ®Google Scholar
• Bellasi A, Reiner M, Pétavy F, et al. Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study. J Heart Valve Dis. 2013;22:391–399.
   PubMed Web of Science ®Google Scholar
• Urena-Torres PA, Floege J, Hawley CM, et al. Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transpl. 2013;28:146–152.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Nistor I, Craig JC, et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med. 2013;10:e1001436.
   PubMed Web of Science ®Google Scholar
• Parfrey PS, Drüeke TB, Block GA, et al. The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol. 2015;10:791–799.
   PubMed Web of Science ®Google Scholar
• Moe SM, Abdalla S, Chertow GM, et al. Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol. 2015;26(6):1466–1475.
   Web of Science ®Google Scholar
• Goldsmith DJA, Covic A, Vervloet M, et al. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transplant. 2015;30(5):698–700.
   PubMed Web of Science ®Google Scholar
• Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793–1800.
   PubMed Web of Science ®Google Scholar
• Urena P, Jacobson SH, Zitt E, et al. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice–the ECHO observational study. Nephrol Dial Transpl. 2009;24:2852–2859.
   PubMed Web of Science ®Google Scholar
• Belozeroff V, Chertow GM, Graham CN, et al. Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value Health. 2015;18:1079–1087.
   PubMed Web of Science ®Google Scholar
• Yusuf AA, Howell BL, Powers CA, et al. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D. Am J Kidney Dis. 2014;64:770–780.
   PubMed Web of Science ®Google Scholar
• Martin KJ, Bell G, Pickthorn K, et al. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transpl. 2014;29:385–392.
   PubMed Web of Science ®Google Scholar
• Martin KJ, Pickthorn K, Huang S, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int. 2014;85:191–197.
   PubMed Web of Science ®Google Scholar
• Bell G, Huang S, Martin KJ, et al. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin. 2015;31:943–952.
   PubMed Web of Science ®Google Scholar
• Chen P, Melhem M, Xiao J, et al. Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. J Clin Pharmacol. 2015;55:620–628.
   PubMed Web of Science ®Google Scholar
• Amgen, Inc. Amgen announces positive phase 3 results for AMG 416 for the treatment of secondary hyperparathyroidis in patients with chronic kidney disease receiving hemodialysis; [ cited 2016 Mar 28]. Available from: http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1948573
   Google Scholar
• Amgen, Inc. Amgen announces positive top-line results from second phase 3 study of AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis; [ cited 2016 Mar 28]. Available from: http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1959215
   Google Scholar
• Amgen, Inc. Amgen announces positive results from head-to-head study comparing the efficacy and safety of AMG 416 with cinacalcet in patients with secondary hyperparathyroidism receiving hemodialysis; [ cited 2016 May 28]. Available from: http://www.amgen.com/media/news-releases/2015/02/amgen-announces-positive-results-from-head-to-head-study-comparing-the-efficacy-and-safety-of-amg-416-with-cinacalcet-in-patients-with-secondary-hyperparathyroidism-receiving-hemodialysis/
   Google Scholar
• Maluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Min Res. 2011;26:2793.
   Web of Science ®Google Scholar
• Bover J, Urena P, Brandenburg V, et al. Adynamic bone disease: from bone to vessels in chronic kidney disease. Semin Nephrol. 2014;34:626–640.
   PubMed Web of Science ®Google Scholar
• Cejka D, Kodras K, Bader T, et al. Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1–34): a pilot study. Kidney Blood Press Res. 2010;33:221–226.
   PubMed Web of Science ®Google Scholar
• Brandenburg V, Adragao T, van Dam B, et al. Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). Clin Kidney J. 2015;8:567–571.
   PubMedGoogle Scholar
• Hayashi M. Calciphylaxis: diagnosis and clinical features. Clin Exp Nephrol. 2013;17:498–503.
   PubMed Web of Science ®Google Scholar
• Floege J, Kubo Y, Floege A, et al. The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: the EVOLVE trial. Clin J Am Soc Nephrol. 2015;10:800–807.
   PubMed Web of Science ®Google Scholar
• Adirekkiat S, Sumethkul V, Ingsathit A, et al. Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transpl. 2010;25:1923–1929.
   PubMed Web of Science ®Google Scholar
• Weijs B, Blaauw Y, Rennenberg RJMW, et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J. 2011;32:2555–2562.
   PubMed Web of Science ®Google Scholar
• Caluwé R, Pyfferoen L, De Boeck K, et al. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. Clin Kidney J. 2016;9:273–279.
   PubMed Web of Science ®Google Scholar
• Perelló J, Salcedo C, Joubert PH, et al. First-time-inhuman phas 1 clinical trial in healthy volunteers with SNF472, a novel inhibitor of vascular calcification [abstract]. Nephrol Dial Trnsplant. 2015;30(suppl 3):ii592.
   Google Scholar
• Bover J, Evenepoel P, Urena-Torres P, et al. Cardiovascular calcifications are clinically relevant. Nephrol Dial Transpl. 2015;30:345–351.
   PubMed Web of Science ®Google Scholar
• Goldsmith DJA, Covic A, Fouque D, et al. Endorsement of the kidney disease improving global outcomes (KDIGO) chronic kidney disease-mineral and bone disorder (CKD-MBD) guidelines: a European renal best practice (ERBP) commentary statement. Nephrol Dial Transpl. 2010;25:3823–3831.
   PubMed Web of Science ®Google Scholar
• Zoccali C, London G. Con: vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease. Nephrol Dial Transpl. 2015;30:352–357.
   PubMed Web of Science ®Google Scholar
• Bover J, Dasilva I, Furlano M, et al. Clinical uses of 1,25-dihydroxy-19-nor-vitamin D2 (Paricalcitol). Curr Vasc Pharmacol. 2014;12:313–323.
   PubMed Web of Science ®Google Scholar
• Mazzaferro S, Goldsmith D, Larsson TE, et al. Vitamin D metabolites and/or analogs: which D for which patient? Curr Vasc Pharmacol. 2014;12:339–349.
   PubMed Web of Science ®Google Scholar
• Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis. 2001;38:S45–50.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Martin KJ, Wolf M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transpl. 2012;27:3270–3278.
   PubMed Web of Science ®Google Scholar
• Zitt E, Fouque D, Jacobson SH, et al. Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. Clin Kidney J. 2013;6:287–294.
   PubMedGoogle Scholar
• Rodriguez ME, Almaden Y, Canadillas S, et al. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol. 2007;292:F1390–F1395.
   PubMed Web of Science ®Google Scholar
• Carrillo-Lopez N, Alvarez-Hernandez D, Gonzalez-Suarez I, et al. Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol. Nephrol Dial Transpl. 2008;23:3479–3484.
   PubMed Web of Science ®Google Scholar
• Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995;311:485.
   PubMed Web of Science ®Google Scholar
• Block G, Isakova T. Tip-toeing toward the finish line. Nephrol Dial Transpl. 2015;30:1–3.
   PubMed Web of Science ®Google Scholar